Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S. Reich, Sibyl Wray, Ema Kantorová et al.|The Lancet Neurology|2021Cited by 192
Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 studyB. Singer, Sibyl Wray, Annette Wundes et al.|Multiple Sclerosis Journal|2023Cited by 23